Compare McKesson Corporation (MCK) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs ProShares UltraPro S&P500 — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while ProShares UltraPro S&P500 trades at $141.66. The key difference: McKesson Corporation pays a 0.39% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | UPRO | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $995.69 | $150.93 |
52-Week Low | $659.01 | $89.29 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
UPRO trades at $138.50, down 0.4% on the day, with technical indicators showing a bearish bias as the stock faces resistance near $140-141 levels. The overall technical signal is bearish with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights broader S&P 500 concerns about valuation levels and market concentration in tech stocks, creating headwinds for leveraged ETFs like UPRO.
The outlook for UPRO remains challenged by elevated market valuations and technical resistance. Investment opportunity exists if the S&P 500 breaks through current resistance levels, but risks include continued market volatility and potential mean reversion in tech-heavy indices. The bearish technical setup suggests caution in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
